NCT00325260

Non-Inferiority Study Comparing the Subunit Vaccines Influvac and Agrippal in China

A Randomized, Endpoint-Blind, Parallel Group Study to Demonstrate the Non-Inferiority of the Subunit Influenza Vaccine Influvac® to the Subunit Influenza Vaccine Agrippal® in Healthy Children, Adults and Elderly in China.

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 900 (planned)
• Sponsor: Solvay Pharmaceuticals · Industry
• Sex: All
• Age: 3 Years
• Healthy volunteers: Accepted

Summary

In the study Influvac will be compared to Agrippal, another subunit influenza vaccine that is already on the market in China. The main objective of the study is to show that both vaccines are comparable with regard to efficacy. In addition, safety and efficacy data with Influvac will be assessed in the Chinese population.

Conditions

• Healthy

Interventions

Type	Name	Description
BIOLOGICAL	Influvac; subunit influenza vaccine

Timeline

• Start date: 2006-03-01
• First posted: 2006-05-12
• Last updated: 2006-11-01

Locations

1 site across 1 country: China